指南与共识痛风与晶体性关节病

G-CAN关于焦磷酸钙晶体沉积(CPPD)疾病要素标签与定义的共识声明

Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in calcium pyrophosphate crystal deposition (CPPD).
指南 / 共识 · Ann Rheum Dis · 2026-06-09

G-CAN通过3轮德尔菲法制定CPPD国际共识术语。共识统一了「焦磷酸钙晶体」和「焦磷酸钙晶体沉积(CPPD)」等标签,将「软骨钙化」重新定义为与CPPD相符的常规放射学软骨钙化,识别四种临床表现并弃用「假性痛风」。该命名旨在解决长期歧义,为研究定义和临床试验同质性提供框架。

要点

  • 共识统一采用「焦磷酸钙晶体沉积(CPPD)」描述沉积过程,影像学统一为「影像学上的焦磷酸钙晶体沉积」。
  • 「软骨钙化」重新定义为常规放射学软骨钙化且符合CPPD,不再作为独立疾病实体。
  • 识别四种临床表现:急性CPP晶体关节炎、慢性CPP晶体关节炎、齿状突加冠综合征、伴CPPD的骨关节炎。

核心结论

  • G-CAN CPPD命名是首个系统性地使CPPD术语与当代生物学和影像学证据对齐的努力,通过解决长期歧义为研究定义、临床试验同质性和患者照护提供框架。

研究设计与样本

  • G-CAN成员受邀参与3轮德尔菲法,指导委员会从2000至2022年系统文献综述中出现在>10%论文里的CPPD病因、病理生理和临床表现要素中确定关键组分,参与者为每个要素选择首选标签。

主要发现

  • 共识达成「焦磷酸钙(CPP)晶体」和「焦磷酸钙晶体沉积(CPPD)」用于描述沉积过程。
  • 跨影像模态采用统一术语「影像学上的焦磷酸钙晶体沉积」,而「软骨钙化」重新定义为与CPPD相符的常规放射学软骨钙化。
  • 识别四种临床表现:急性CPP晶体关节炎(急性发作称「 flare」)、慢性CPP晶体关节炎、齿状突加冠综合征和伴CPPD的骨关节炎;「假性痛风」未获支持。
  • 该病症现分类为「无症状CPPD」或症状性表现时的「CPPD疾病」。

关键数值与推荐

  • 系统文献综述覆盖2000至2022年出版物,指导委员会纳入出现在>10%论文中的要素。
  • 共识通过3轮德尔菲法达成。

临床怎么用

  • 临床应使用「急性CPP晶体关节炎」替代「假性痛风」,以「 flare」描述急性发作。
  • 影像学报告统一使用「影像学上的焦磷酸钙晶体沉积」,避免将「软骨钙化」误作独立诊断。
  • 根据症状有无区分「无症状CPPD」与「CPPD疾病」,并采用四种临床表现分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: A systematic literature review (SLR) of publications from 2000 to 2022 identified terminology for calcium pyrophosphate crystal deposition (CPPD) and revealed substantial heterogeneity and poor adherence to recommendations. This study aimed to standardise CPPD terminology by developing an international consensus on labels and definitions. METHODS: Members of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) were invited by email to participate in a 3-round Delphi exercise. A steering committee identified key components of CPPD aetiology, pathophysiology, and clinical presentation among elements appearing in >10% of SLR papers, adding or removing items when scientifically justified. Participants selected preferred labels for each element. Respondents to the first round were invited to subsequent rounds. This paper reports the resulting G-CAN CPPD nomenclature. RESULTS: Consensus was reached for 'calcium pyrophosphate (CPP) crystal' and 'calcium pyrophosphate crystal deposition (CPPD)' to describe the deposition process. The unified term 'calcium pyrophosphate crystal deposition on imaging' was adopted across imaging modalities, whereas 'chondrocalcinosis' was redefined as conventional radiographic cartilage calcification consistent with CPPD. Four clinical manifestations were identified: 'acute CPP crystal arthritis' (with 'flare' for acute episodes), 'chronic CPP crystal arthritis', 'crowned dens syndrome', and 'osteoarthritis with CPPD'; the term 'pseudogout' received no support. The condition is now classified as 'asymptomatic CPPD' or 'CPPD disease' for symptomatic presentations. CONCLUSIONS: This G-CAN nomenclature is the first systematic effort to align CPPD terminology with contemporary biological and imaging evidence. By resolving longstanding ambiguities-particularly regarding 'chondrocalcinosis'-it provides a framework for consistent research definitions, clinical trial homogeneity, and improved patient care.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Filippou G, Pezzoni L, Filippucci E, et al. Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in calcium pyrophosphate crystal deposition (CPPD). Ann Rheum Dis. 2026. PMID: 42264993. doi:10.1016/j.ard.2026.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。